Topline Results Negative for MS Drug in Acute Stroke Topline Results Negative for MS Drug in Acute Stroke
After natalizumab showed some initial promise in improving clinical outcomes in acute ischemic stroke in a phase 2a study, a phase 2b trial of the drug finds no clinical benefit.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 9, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Pregnant MS Patients Face Extra Relapse Risk with Natalizumab Holiday (CME/CE)
(MedPage Today) -- Avoiding washout, resuming treatment early may improve outcomes (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - February 8, 2018 Category: Neurology Source Type: news
MS Drug Poses Hard Choices for Women Wanting Kids
Those who take Tysabri (natalizumab) to manage their MS are more likely to suffer a relapse during pregnancy if they stop taking the drug before they conceive, the first study found. (Source: WebMD Health)
Source: WebMD Health - February 8, 2018 Category: Consumer Health News Source Type: news
MS Drug Tysabri (Natalizumab) Poses Hard Choices for Women Wanting Children
THURSDAY, Feb. 8, 2018 -- A powerful multiple sclerosis drug presents women with a tough dilemma if they would like to have children, a pair of new studies suggests.
Those who take Tysabri (natalizumab) to manage their MS are more likely to suffer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 8, 2018 Category: General Medicine Source Type: news
Biogen stops testing Tysabri to treat stroke after study fails
(Reuters) - Biogen Inc said on Wednesday it would stop developing its multiple sclerosis drug Tysabri to treat patients with acute ischemic stroke after it failed a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Biogen stops developing Tysabri to treat stroke after failed study
(Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk
Extended-interval dosing of natalizumab was associated with a 94% lower risk for progressive multifocal leukoencephalopathy vs standard dosing in patients with MS positive for anti-JC virus antibody.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 3, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Extending dosing intervals reduces deadly side effect risk from multiple sclerosis drug
(NYU Langone Health / NYU School of Medicine) A commonly-prescribed multiple sclerosis (MS) infusion medication, natalizumab, linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS specialists at NYU Langone Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2018 Category: International Medicine & Public Health Source Type: news
Rituximab Outperforms Other Drugs in RRMS Rituximab Outperforms Other Drugs in RRMS
In a new study, rituximab was superior to other drugs -- including fingolimod, natalizumab, and dimethyl fumarate -- in efficacy, safety, and tolerability in patients with relapsing-remitting MS.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Dimethyl Fumarate: A Possible Exit Strategy From Natalizumab Dimethyl Fumarate: A Possible Exit Strategy From Natalizumab
Is dimethyl fumarate effective in preventing disease rebound after natalizumab discontinuation in patients with MS?Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
[01-20-2012] The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news
Natalizumab Beneficial in Secondary Progressive MS? Natalizumab Beneficial in Secondary Progressive MS?
A new post hoc analysis of the ASCEND trial in secondary progressive multiple sclerosis suggests that natalizumab is effective in this population, particularly for upper limb function.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
PML Reported in Patient Receiving Ocrelizumab PML Reported in Patient Receiving Ocrelizumab
But the case could be attributable to ' carryover ' from the patient ' s previous treatment with natalizumab, the company said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Genentech Reports PML Case with Ocrelizumab
(MedPage Today) -- Occurred in patient transitioning from natalizumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 24, 2017 Category: Primary Care Source Type: news
Enhanced Atypical Lymphocytes in Natalizumab - Treated MS
Enhanced fraction of atypical lymphocytes, especially binucleated and plasmacytoid lymphocytes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 24, 2017 Category: Cancer & Oncology Tags: Internal Medicine, Neurology, Oncology, Pathology, Pharmacy, Journal, Source Type: news
